Immunogenicity profile of lanadelumab, a fully human monoclonal antibody plasma kallikrein inhibitor, for the prevention of angioedema attacks in patients with hereditary angioedema

被引：0
|
作者：
Maurer, M. [1 ]
Zuraw, B. L. [2 ]
Sexton, D. J. [3 ]
Theobald, V [3 ]
机构：
[1] Charite, Allergie Ctr Charite, Dept Dermatol & Allergy, Berlin, Germany
[2] Univ Calif San Diego, Dept Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA
[3] Shire, Lexington, MA USA
来源：
ALLERGY | 2017年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
0118
引用
收藏
页码：99 / 100
页数：2
相关论文
共 50 条
  • [1] Lanadelumab for the prevention of attacks in hereditary angioedema
    Valerieva, Anna
    Senter, Riccardo
    Wu, Maddalena Alessandra
    Zanichelli, Andrea
    Cicardi, Marco
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (12) : 1239 - 1248
  • [2] A review of kallikrein inhibitor lanadelumab in hereditary angioedema
    Hwang, Gloria
    Johri, Ansh
    Ng, Sally
    Craig, Timothy
    [J]. IMMUNOTHERAPY, 2019, 11 (11) : 937 - 944
  • [3] ECALLANTIDE: A PLASMA KALLIKREIN INHIBITOR FOR THE TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA
    Stolz, L. E.
    Horn, P. T.
    [J]. DRUGS OF TODAY, 2010, 46 (08) : 547 - 555
  • [4] Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
    Riedl, Marc A.
    Maurer, Marcus
    Bernstein, Jonathan A.
    Banerji, Aleena
    Longhurst, Hilary J.
    Li, H. Henry
    Lu, Peng
    Hao, James
    Juethner, Salome
    Lumry, William R.
    [J]. ALLERGY, 2020, 75 (11) : 2879 - 2887
  • [5] RELEVANCE OF PLASMA KALLIKREIN (PKAL) LEVELS FOR LANADELUMAB PHARMACOKINETICS (PK) IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE).
    Ahmed, M.
    Wang, Y.
    Zhu, A.
    Sexton, D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S5 - S6
  • [6] Ecallantide - Plasma kallikrein inhibitor, treatment of hereditary angioedema
    Revill, P.
    Mealy, N.
    [J]. DRUGS OF THE FUTURE, 2007, 32 (07) : 590 - 594
  • [7] Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
    Aygoeren-Puersuen, E.
    Bygum, A.
    Grivcheva-Panovska, V.
    Magerl, M.
    Graff, J.
    Steiner, U. C.
    Fain, O.
    Huissoon, A.
    Kinaciyan, T.
    Farkas, H.
    Lleonart, R.
    Longhurst, H. J.
    Rae, W.
    Triggiani, M.
    Aberer, W.
    Cancian, M.
    Zanichelli, A.
    Smith, W. B.
    Baeza, M. L.
    Du-Thanh, A.
    Gompels, M.
    Gonzalez-Quevedo, T.
    Greve, J.
    Guilarte, M.
    Katelaris, C.
    Dobo, S.
    Cornpropst, M.
    Clemons, D.
    Fang, L.
    Collis, P.
    Sheridan, W.
    Maurer, M.
    Cicardi, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (04): : 352 - 362
  • [8] Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit
    Dorr, Anthony D.
    Chopra, Charu
    Coulter, Tanya I.
    Dempster, John
    Dziadzio, Magdalena
    El-Shanawany, Tariq
    Garcez, Tomaz
    Gompels, Mark
    Herriot, Richard
    Jain, Rashmi
    Levi, Marcel
    Lorenzo, Lorena
    Makki, Inas
    Mapazire, Elizabeth
    Murng, Sai H. K.
    Noorani, Sadia
    Savic, Sinisa
    Steele, Cathal L.
    Symons, Christine
    Tarzi, Michael
    Yong, Patrick F. K.
    Kiani-Alikhan, Sorena
    [J]. ALLERGY, 2023, 78 (05) : 1369 - 1371
  • [9] PLASMA KALLIKREIN AND PRORENIN IN PATIENTS WITH HEREDITARY ANGIOEDEMA
    PURDON, AD
    SCHAPIRA, M
    DEAGOSTINI, A
    COLMAN, RW
    [J]. JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1985, 105 (06): : 694 - 699
  • [10] Berotralstat Plasma kallikrein (KLKB1) inhibitor Treatment of hereditary angioedema attacks
    Gras, J.
    [J]. DRUGS OF THE FUTURE, 2021, 46 (01) : 21 - 28
12345